Effects of chymostatin, a chymase inhibitor, on blood pressure, plasma and tissue angiotensin II, renal haemodynamics and renal excretion in two models of hypertension in the rat

Experimental Physiology

Volumn 100, Issue 9, 2015, Pages 1093-1105

  Roszkowska Chojecka, Malwina Monika ^a   Walkowska, Agnieszka ^a   Gawryś, Olga ^a   Baranowska, Iwona ^a   Kalisz, Małgorzata ^b   Litwiniuk, Anna ^b   Martyńska, Lidia ^b   Kompanowska Jezierska, Elzbieta ^a  

^a MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; CHYMASE; CHYMOSTATIN; ELASTASE; ELASTASE 2; HORMONE; POTASSIUM; SODIUM; UNCLASSIFIED DRUG; DIPEPTIDYL CARBOXYPEPTIDASE; OLIGOPEPTIDE;

ANGIOTENSIN BLOOD LEVEL; ANGIOTENSIN TISSUE LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; GLOMERULUS FILTRATION RATE; HEART RATE; HORMONE BLOOD LEVEL; IN VIVO STUDY; KIDNEY ARTERY STENOSIS; KIDNEY BLOOD FLOW; KIDNEY VASCULAR RESISTANCE; LIMB PERFUSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PLASMA OSMOLALITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PROTEIN SYNTHESIS; RAT; RENOVASCULAR HYPERTENSION; SODIUM BLOOD LEVEL; SODIUM URINE LEVEL; TISSUE LEVEL; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY EXCRETION; VASCULAR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD PRESSURE; DRUG EFFECTS; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; KIDNEY; KIDNEY CIRCULATION; METABOLISM; SPRAGUE DAWLEY RAT;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CHYMASES; GLOMERULAR FILTRATION RATE; HEMODYNAMICS; HYPERTENSION, RENOVASCULAR; KIDNEY; MALE; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RATS; RATS, SPRAGUE-DAWLEY; RENAL CIRCULATION; RENAL ELIMINATION;

EID: 84940608711     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/EP085325     Document Type: Article

References (52)

1. Ahmad S, Wei CC, Tallaj J, Dell'Italia LJ, Moniwa N, Varagic J & Ferrario CM (2013). Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 7, 128-136.
2. Badzyńska B & Sadowski J (2012). Experimental selective elevation of renal medullary blood flow in hypertensive rats: evidence against short-term hypotensive effect. Acta Physiol (Oxf) 205, 484-493.
3. Baltatu O, Nishimura H, Hoffmann S, Stoltenburg G, Haulica ID & Lippoldt A (1997). High levels of human chymase expression in the pineal and pituitary glands. Brain Res 752, 269-278.
4. Campbell DJ, Lawrence AC, Towrie A, Kladis A & Valentijn AJ (1991). Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 18, 763-73.
5. Caughey GH, Leidig F, Viro NF & Nadel JA (1988). Substance P and vasoactive intestinal peptide degradation by mast cell tryptase and chymase. J Pharmacol Exp Ther 244, 133-137.
6. Chatterjee PK, Brown PA, Cuzzocrea S, Zacharowski K, Stewart KN, Mota-Filipe H, McDonald MC & Thiemermann C (2001). Calpain inhibitor-1 reduces renal ischemia/reperfusion injury in the rat. Kidney Int 59, 2073-2083.
7. Cowley AW Jr (1992). Long-term control of arterial blood pressure. Physiol Rev 72, 231-300.
8. Crestani S, JúniorAG, Marques MCA, Sullivan JC, Webb RC & Silva-Santos JE (2014). Enhanced angiotensin-converting enzyme activity and systemic reactivity to angiotensin II in normotensive rats exposed to a high-sodium diet. Vascul Pharmacol 60, 67-74.
9. Doggrell SA & Wanstall JC (2004). Vascular chymase: pathophysiological role and therapeutic potential of inhibition. Cardiovasc Res 61, 653-662.
10. Dubourg L, Hadj-Aïssa A & Ferrier B (2010). Adaptation of an enzymatic polyfructosan assay to clinical practice. Anal Biochem 405, 266-268.
11. Dzau VJ & Pratt RE (1986). Renin-angiotensin system: biology, physiology, and pharmacology. In The Heart and Cardiovascular System, eds. Haber E, Morgan H, Katz A, Fozzard H pp. 1631-1661. Raven Press, New York.
12. Guan S, Fox J, Mitchell KD & Navar LG (1992). Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats. Hypertension 20, 763-767.
13. Guo C, Ju H, Leung D, Massaeli H, Shi M & Rabinovitch M (2001). A novel vascular smooth muscle chymase is upregulated in hypertensive rats. J Clin Invest 107, 703-715.
14. + in 2 congenic strains of Dahl salt-sensitive rats. Hypertension 49, 1315-1320.
15. Huang BS & Leenen FH (1998). Both brain angiotensin II and 'ouabain' contribute to sympathoexcitation and hypertension in Dahl S rats on high salt intake. Hypertension 35, 1028-1033.
16. Imig JD (2015) Epoxyeicosatrienoic acids, hypertension, and kidney injury. Hypertension 65, 476-482.
17. Ju H, Gros R, You X, Tsang S, Husain M & Rabinovitch M (2001). Conditional and targeted overexpression of vascular chymase causes hypertension in transgenic mice. Proc Natl Acad Sci USA 98, 7469-7474.
18. Kassell NF, Sprowell JA, Boarini DJ & Olin JJ (1983). Effect of dimethyl sulfoxide on the cerebral and systemic circulations of the dog. Neurosurgery 12, 24-28.
19. Kirimura K, Takai S, Jin D, Muramatsu M, Kishi K, Yoshikawa K, Nakabayashi M, Mino Y & Miyazaki M (2005). Role of chymase-dependent angiotensin II formation in regulating blood pressure in spontaneously hypertensive rats. Hypertens Res 28, 457-64.
20. Kokkonen JO, Lindstedt KA & Kovanen PT (2003). Role for chymase in heart failure: angiotensin II-dependent or -independent mechanisms? Circulation 107, 2522-2524.
21. Leenen FH & Yuan B (2001). Prevention of hypertension by irbesartan in Dahl S rats relates to central angiotensin II type 1 receptor blockade. Hypertension 37, 981-984.
22. Li M, Liu K, Michalicek J, Angus JA, Hunt JE, Dell'Italia LJ, Feneley MP, Graham RM & Husain A (2004). Involvement of chymase-mediated angiotensin II generation in blood pressure regulation. J Clin Invest 114, 112-120.
23. Liang B & Leenen FHH (2007). Prevention of salt induced hypertension and fibrosis by angiotensin converting enzyme inhibitors in Dahl S rats. Br J Pharmacol 152, 903-914.
24. Lorenz JN (2010). Chymase: the other ACE? Am J Physiol Renal Physiol 298, F35-F36.
25. 12] angiotensin I in human dorsal hand veins: in vivo demonstration of non-ACE production of angiotensin II in humans. Circulation 104, 1805-1808.
26. Miyake-Ogawa C, Miyzaki M, Abe K, Harade T, Ozono Y, Sakai H, Koji T & Kohno S (2005). Tissue speccific expression of renin-angiotensin system components in IgA nephropathy. Am J Nephrol 25, 1-12.
27. Moniwa N, Varagic J, Simington SW, Ahmad S, Nagata S, VonCannon JL & Ferrario CM (2013). Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Circ Physiol 305, H644-H650.
28. Navar LG, Harrison-Bernard LM & Imig JD (1998). Compartmentalization of intrarenal angiotensin II. In Renin-Angiotensin, ed. Ulfendahl HR & Aurell M, 193-208. Portland Press, London.
29. Navar LG, Imig JD, Zou L & Wang C-T (1997). Intrarenal production of angiotensin II. Sem Nephrol 17, 412-422.
30. Navar LG, Zou L, VonThun A, Wang CT, Imig JD & Mitchell KD (1998). Unraveling the mystery of Goldblatt hypertension. News Physiol Sci 13, 170-176.
31. Okamura T, Okunishi H, Ayajiki K & Toda N (1990). Conversion of angiotensin I to angiotensin II in dog isolated artery: role of two different angiotensin II-generating enzymes. J Cardiovasc Pharmacol 15, 353-359.
32. Okunishi H, Miyazaki M, Okamura T & Toda N (1987). Different distribution of two types of angiotensin II-generating enzymes in the aortic wall. Biochem Biophys Res Commun 149, 1186-1192.
33. Okunishi H, Miyazaki M & Toda N (1984). Evidence for a putatively new angiotensin II-generating enzyme in the vascular wall. J Hypertens 2, 277-284.
34. Pallone TL (1994). Vasoconstriction of outer medullary vasa recta by angiotensin II is modulated by prostaglandin E2. Am J Physiol Renal Physiol 266, F850-F857.
35. Paula CA, Sousa MV, Salgado MC & Oliveira EB (1998). Purification and substrate specificity of an angiotensin converting elastase-2 from the rat mesenteric arterial bed perfusate. Biochim Biophys Acta 1388, 227-238.
36. Petrie MC, Padmanabhan N, McDonald JE, Hillier C, Connell JM & McMurray JJ (2001). Angiotensin converting enzyme (ACE) and non-ACE dependent angiotensin II generation in resistance arteries from patients with heart failure and coronary heart disease. J Am Coll Cardiol 37, 1056-1061.
37. Pitts LH, Young AR, McCulloch J & MacKenzie E (1986). Vasomotor effects of dimethyl sulfoxide on cat cerebral arteries in vitro and in vivo. Stroke 17, 483-487.
38. Reams G, Villarreal D, Wu Z & Bauer JH (1993). Renal tissue angiotensin II: response to infusions of angiotensin I and an angiotensin-converting enzyme inhibitor. Am J Kidney Dis 22, 851-857.
39. Reilly CF, Schechter NB & Travis J (1985). Inactivation of bradykinin and kallidin by cathepsin G and mast cell chymase. Biochem Biophys Res Commun 127, 443-449.
40. Reilly CF, Tewksbury DA, Schechter NM & Travis J (1982). Rapid conversion of angiotensin I to angiotensin II by neutrophil and mast cell proteinases. J Biol Chem 257, 8619-8622.
41. Richard V, Hurel-Merle S, Scalbert E, Ferry G, Lallemand F & Bessou JP (2001). Functional evidence for a role of vascular chymase in the production of angiotensin II in isolated human arteries. Circulation 104, 750-752.
42. Rosivall L, Narkates AJ, Oparil S & Navar LG (1987). De novo intrarenal formation of angiotensin II during control and enhanced renin secretion. Am J Physiol Renal Physiol 252, F1118-F1123.
43. Sadjadi J, Kramer GL, Yu CH, Burress Welborn M III, Chappell MC & Gregory Modrall J (2005). Angiotensin converting enzyme-independent angiotensin II production by chymase is up-regulated in the ischemic kidney in renovascular hypertension. J Surg Res 127, 65-69.
44. Santos CF, Caprio MA, Oliveira EB, Salgado MC, Schippers DN & Munzenmaier DH (2003). Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 285, H775-H783.
45. Santos CF, Paula CA, Salgado MC & Oliveira EB (2002). Kinetic characterization and inhibition of the rat MAB elastase-2, an angiotensin I-converting serine protease. Can J Physiol Pharmacol 80, 42-47.
46. Schick B, Austen KF & Schwartz LB (1984). Activation of rat serosal mast cells by chymase, an endogenous secretory granule protease. J Immunol 132, 2571-2577.
47. Simard E, Jin D, Takai S, Miyazaki M, Brochu I & D'Orléans-Juste P (2009). Chymase-dependent conversion of Big endothelin-1 in the mouse in vivo. J Pharmacol Exp Ther 328, 540-548.
48. Takai S, Jin D, Muramatsu M & Miyazaki M (2004). Chymase as a novel target for the prevention of vascular diseases. Trends Pharmacol Sci 25, 518-522.
49. Urata H (2000). Pathological involvement of chymase-dependent angiotensin II formation in the development of cardiovascular disease. J Renin Angiotensin Aldosterone Syst 1, 35-37.
50. Urata H, Healy B, Stewart RW, Bumpus FM & Husain A (1990a). Angiotensin -forming pathways in normal and failing human hearts. Circ Res 66, 883-890.
51. Urata H, Kinoshita A, Misono KS, Bumpus FM & Husain A (1990b). Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265, 22348-22357.
52. Von Thun AM, Vari RC, El-Dahr SS & Navar LG (1994). Augmentation of intrarenal angiotensin II levels by chronic angiotensin II infusion. Am J Physiol Renal Physiol 266, F120-F128.